Journal for immunotherapy of cancer

Keyphrases

Publications

volume 12, number 8, 2024

Xin Zheng, Luyu Yang, Xiaotian Shen, Junjie Pan, Yiran Chen, Jixuan Chen, Hao Wang, Jiaqi Meng, Zhenchao Chen, Sunzhe Xie, Yitong Li, Bolun Zhu, Wenwei Zhu, Lunxiu Qin, Lu Lu
Targeting Gsk3a reverses immune evasion to enhance immunotherapy in hepatocellular carcinoma. Journal for immunotherapy of cancer 12 (8) (2024)
Xin Zheng, Luyu Yang, Xiaotian Shen, Junjie Pan, Yiran Chen, Jixuan Chen, Hao Wang, Jiaqi Meng, Zhenchao Chen, Sunzhe Xie, Yitong Li, Bolun Zhu, Wenwei Zhu, Lunxiu Qin, Lu Lu
Targeting Gsk3a reverses immune evasion to enhance immunotherapy in hepatocellular carcinoma. Journal for immunotherapy of cancer 12 (8) (2024)
Ludimila Cavalcante, Sreenivasa Chandana, Nehal J Lakhani, Amanda Enstrom, Heidi LeBlanc, Joseph Schmalz, Krisztina Lengyel, Frank Schneider, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski, Diwakar Davar
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab. Journal for immunotherapy of cancer 12 (8) (2024)
Kristin DePeaux, William G Gunn, Dayana B Rivadeneira, Greg M Delgoffe
Treatment with oncolytic vaccinia virus infects tumor-infiltrating regulatory and exhausted T cells. Journal for immunotherapy of cancer 12 (8) (2024)
Xun-Xi Lu, Zongchao Gou, Hong Chen, Li Li, Fei Chen, Chunjuan Bao, Hong Bu
Gene panel predicts neoadjuvant chemoimmunotherapy response and benefit from immunotherapy in HER2-negative breast cancer. Journal for immunotherapy of cancer 12 (8) (2024)
Kensuke Nakagawara, Makoto Ando, Tanakorn Srirat, Setsuko Mise-Omata, Taeko Hayakawa, Minako Ito, Koichi Fukunaga, Akihiko Yoshimura
NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors. Journal for immunotherapy of cancer 12 (8) (2024)
Xueyuan Lyu, Linlin Zhao, Sijia Chen, Yulu Li, Yajing Yang, Huisi Liu, Fang Yang, Wenhui Li, Jianhua Sui
Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8 + T cells and inhibited tumor growth. Journal for immunotherapy of cancer 12 (8) (2024)
Kensuke Nakagawara, Makoto Ando, Tanakorn Srirat, Setsuko Mise-Omata, Taeko Hayakawa, Minako Ito, Koichi Fukunaga, Akihiko Yoshimura
NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors. Journal for immunotherapy of cancer 12 (8) (2024)
Diwakar Davar, Ludimila Cavalcante, Nehal J Lakhani, Justin C Moser, Michael Millward, Meredith McKean, Mark Voskoboynik, Rachel E Sanborn, Jaspreet S Grewal, Ajita Narayan, Amita Patnaik, Justin F Gainor, Mario Sznol, Amanda Enstrom, Lori Blanchfield, Heidi LeBlanc, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). Journal for immunotherapy of cancer 12 (8) (2024)
Lambert Assoumou, Raghiatou Baldé, Christine Katlama, Baptiste Abbar, Pierre Delobel, Thierry Allegre, Armelle Lavole, Alain Makinson, Olivia Zaegel-Faucher, Laurent Greillier, Cathia Soulie, Marianne Veyri, Mathilde Bertheau, Michèle Algarte Genin, Séverine Gibowski, Anne-Geneviève Marcelin, Kevin Bihan, Marine Baron, Dominique Costagliola, Olivier Lambotte, Jean-Philippe Spano
Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study. Journal for immunotherapy of cancer 12 (8) (2024)
Kensuke Nakagawara, Makoto Ando, Tanakorn Srirat, Setsuko Mise-Omata, Taeko Hayakawa, Minako Ito, Koichi Fukunaga, Akihiko Yoshimura
NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors. Journal for immunotherapy of cancer 12 (8) (2024)
Diwakar Davar, Ludimila Cavalcante, Nehal J Lakhani, Justin C Moser, Michael Millward, Meredith McKean, Mark Voskoboynik, Rachel E Sanborn, Jaspreet S Grewal, Ajita Narayan, Amita Patnaik, Justin F Gainor, Mario Sznol, Amanda Enstrom, Lori Blanchfield, Heidi LeBlanc, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). Journal for immunotherapy of cancer 12 (8) (2024)
Xun-Xi Lu, Zongchao Gou, Hong Chen, Li Li, Fei Chen, Chunjuan Bao, Hong Bu
Gene panel predicts neoadjuvant chemoimmunotherapy response and benefit from immunotherapy in HER2-negative breast cancer. Journal for immunotherapy of cancer 12 (8) (2024)
Ludimila Cavalcante, Sreenivasa Chandana, Nehal J Lakhani, Amanda Enstrom, Heidi LeBlanc, Joseph Schmalz, Krisztina Lengyel, Frank Schneider, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski, Diwakar Davar
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab. Journal for immunotherapy of cancer 12 (8) (2024)
Tao Chen, Jiangang Liu, Chenci Wang, Zhengwei Wang, Jiayi Zhou, Jiani Lin, Jie Mao, Tingzheng Pan, Jianwei Wang, Hongchao Xu, Xiaosheng He, Dinglan Wu, Zhuohao Liu
ALOX5 contributes to glioma progression by promoting 5-HETE-mediated immunosuppressive M2 polarization and PD-L1 expression of glioma-associated microglia/macrophages. Journal for immunotherapy of cancer 12 (8) (2024)
Xin Zheng, Luyu Yang, Xiaotian Shen, Junjie Pan, Yiran Chen, Jixuan Chen, Hao Wang, Jiaqi Meng, Zhenchao Chen, Sunzhe Xie, Yitong Li, Bolun Zhu, Wenwei Zhu, Lunxiu Qin, Lu Lu
Targeting Gsk3a reverses immune evasion to enhance immunotherapy in hepatocellular carcinoma. Journal for immunotherapy of cancer 12 (8) (2024)
Kristin DePeaux, William G Gunn, Dayana B Rivadeneira, Greg M Delgoffe
Treatment with oncolytic vaccinia virus infects tumor-infiltrating regulatory and exhausted T cells. Journal for immunotherapy of cancer 12 (8) (2024)
Bolun Zhou, Fan Zhang, Wei Guo, Shuhang Wang, Ning Li, Bin Qiu, Liang Zhao, Jian Li, Kang Shao, Qi Xue, Fang Lv, Shugeng Gao
Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer. Journal for immunotherapy of cancer 12 (8) (2024)
Yongyuan Chen, Zheyu Shao, Zhixing Hao, Zhongwei Xin, Xiaoke Chen, Lijian Huang, Di Chen, Mingjie Lin, Qinyuan Liu, Xia Xu, Jinfan Li, Dang Wu, Jun Yan, Ying Chai, Pin Wu
Epithelium/imcDC2 axis facilitates the resistance of neoadjuvant anti-PD-1 in human NSCLC. Journal for immunotherapy of cancer 12 (8) (2024)
Xueyuan Lyu, Linlin Zhao, Sijia Chen, Yulu Li, Yajing Yang, Huisi Liu, Fang Yang, Wenhui Li, Jianhua Sui
Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8 + T cells and inhibited tumor growth. Journal for immunotherapy of cancer 12 (8) (2024)
Tao Chen, Jiangang Liu, Chenci Wang, Zhengwei Wang, Jiayi Zhou, Jiani Lin, Jie Mao, Tingzheng Pan, Jianwei Wang, Hongchao Xu, Xiaosheng He, Dinglan Wu, Zhuohao Liu
ALOX5 contributes to glioma progression by promoting 5-HETE-mediated immunosuppressive M2 polarization and PD-L1 expression of glioma-associated microglia/macrophages. Journal for immunotherapy of cancer 12 (8) (2024)
Cesare Di Nitto, Domenico Ravazza, Ettore Gilardoni, Thomas Look, Miaomiao Sun, Eleonora Prodi, Vlad Moisoiu, Christian Pellegrino, Markus G Manz, Emanuele Puca, Michael Weller, Tobias Weiss, Dario Neri, Roberto De Luca
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade. Journal for immunotherapy of cancer 12 (8) (2024)
Kristin DePeaux, William G Gunn, Dayana B Rivadeneira, Greg M Delgoffe
Treatment with oncolytic vaccinia virus infects tumor-infiltrating regulatory and exhausted T cells. Journal for immunotherapy of cancer 12 (8) (2024)
Bolun Zhou, Fan Zhang, Wei Guo, Shuhang Wang, Ning Li, Bin Qiu, Liang Zhao, Jian Li, Kang Shao, Qi Xue, Fang Lv, Shugeng Gao
Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer. Journal for immunotherapy of cancer 12 (8) (2024)
Kensuke Nakagawara, Makoto Ando, Tanakorn Srirat, Setsuko Mise-Omata, Taeko Hayakawa, Minako Ito, Koichi Fukunaga, Akihiko Yoshimura
NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors. Journal for immunotherapy of cancer 12 (8) (2024)
Xueyuan Lyu, Linlin Zhao, Sijia Chen, Yulu Li, Yajing Yang, Huisi Liu, Fang Yang, Wenhui Li, Jianhua Sui
Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8 + T cells and inhibited tumor growth. Journal for immunotherapy of cancer 12 (8) (2024)
Lambert Assoumou, Raghiatou Baldé, Christine Katlama, Baptiste Abbar, Pierre Delobel, Thierry Allegre, Armelle Lavole, Alain Makinson, Olivia Zaegel-Faucher, Laurent Greillier, Cathia Soulie, Marianne Veyri, Mathilde Bertheau, Michèle Algarte Genin, Séverine Gibowski, Anne-Geneviève Marcelin, Kevin Bihan, Marine Baron, Dominique Costagliola, Olivier Lambotte, Jean-Philippe Spano
Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study. Journal for immunotherapy of cancer 12 (8) (2024)
Cesare Di Nitto, Domenico Ravazza, Ettore Gilardoni, Thomas Look, Miaomiao Sun, Eleonora Prodi, Vlad Moisoiu, Christian Pellegrino, Markus G Manz, Emanuele Puca, Michael Weller, Tobias Weiss, Dario Neri, Roberto De Luca
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade. Journal for immunotherapy of cancer 12 (8) (2024)
Yongyuan Chen, Zheyu Shao, Zhixing Hao, Zhongwei Xin, Xiaoke Chen, Lijian Huang, Di Chen, Mingjie Lin, Qinyuan Liu, Xia Xu, Jinfan Li, Dang Wu, Jun Yan, Ying Chai, Pin Wu
Epithelium/imcDC2 axis facilitates the resistance of neoadjuvant anti-PD-1 in human NSCLC. Journal for immunotherapy of cancer 12 (8) (2024)
Ludimila Cavalcante, Sreenivasa Chandana, Nehal J Lakhani, Amanda Enstrom, Heidi LeBlanc, Joseph Schmalz, Krisztina Lengyel, Frank Schneider, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski, Diwakar Davar
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab. Journal for immunotherapy of cancer 12 (8) (2024)
Tao Chen, Jiangang Liu, Chenci Wang, Zhengwei Wang, Jiayi Zhou, Jiani Lin, Jie Mao, Tingzheng Pan, Jianwei Wang, Hongchao Xu, Xiaosheng He, Dinglan Wu, Zhuohao Liu
ALOX5 contributes to glioma progression by promoting 5-HETE-mediated immunosuppressive M2 polarization and PD-L1 expression of glioma-associated microglia/macrophages. Journal for immunotherapy of cancer 12 (8) (2024)
Jose Paulo Martins, Rochelle C J D'Souza, Niclas Skarne, Lea Lekieffre, Shane Horsefield, Madusha Ranjankumar, Xiang Li, Thuy T Le, Fiona Smith, Corey Smith, Jacqueline Burrows, Bryan W Day, Rajiv Khanna
EphA3 CAR T cells are effective against glioblastoma in preclinical models. Journal for immunotherapy of cancer 12 (8) (2024)

volume 12, number 9, 2024

Remziye E Wessel, Nardin Ageeb, Joseph M Obeid, Ileana S Mauldin, Kate A Goundry, Gabriel F Hanson, Mahdin Hossain, Chad Lehman, Ryan D Gentzler, Nolan A Wages, Craig L Slingluff, Timothy N J Bullock, Sepideh Dolatshahi, Michael G Brown
Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer. Journal for immunotherapy of cancer 12 (9) (2024)
Ting Wang, Yazi Yang, Lie Ma, Ru Feng, Jiangtao Li, Chunli Zhang, Jiefei Bai, Yanping Ding, Guanghua Liu, Fei Wu, Xinan Lu, Shi Feng, Zhenling Li, Ting He, Jian Li, Hongmei Jing
BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma. Journal for immunotherapy of cancer 12 (9) (2024)
Feyza Gul Ozbay Kurt, Beatrice-Ana Cicortas, Bianca M Balzasch, Carolina De la Torre, Volker Ast, Ece Tavukcuoglu, Cagla Ak, Sebastian A Wohlfeil, Adelheid Cerwenka, Jochen Utikal, Viktor Umansky
S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling. Journal for immunotherapy of cancer 12 (9) (2024)
Lunbiao Gan, Tong Lu, Yu Lu, Hongtao Song, Jiayu Zhang, Keying Zhang, Shiqi Lu, Xinjie Wu, Fengze Nie, Sijia Di, Donghui Han, Fa Yang, Weijun Qin, Weihong Wen
Endosialin-positive CAFs promote hepatocellular carcinoma progression by suppressing CD8 + T cell infiltration. Journal for immunotherapy of cancer 12 (9) (2024)
Iñaki Eguren, Eva Fernández de Piérola, Gracián Camps, Paula Martín-Muñoz, María Campos, Doina Cuculescu, Inmaculada Aguilera-Buenosvinos, Inmaculada Rodríguez López, Rafael Salido-Vallejo, Raluca Alexandru, Carlos E De Andrea, Laura Álvarez-Gigli, Pedro Berraondo, Ignacio Melero Bermejo, Miguel F Sanmamed
MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers. Journal for immunotherapy of cancer 12 (9) (2024)
Wen Luo, Hai Hoang, Hongwen Zhu, Katherine Miller, Xiaokui Mo, Shiori Eguchi, Meijuan Tian, Yanling Liao, Janet Ayello, Jeremy M Rosenblum, Mario Marcondes, Mark Currier, Elaine Mardis, Timothy P Cripe, Amanda J Lee, Mitchell S Cairo
Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy. Journal for immunotherapy of cancer 12 (9) (2024)
Si Chen, Jiakai Hou, Roshni Jaffery, Ashley Guerrero, Rongjie Fu, Leilei Shi, Ningbo Zheng, Ritu Bohat, Nicholas A Egan, Chengtai Yu, Sana Sharif, Yue Lu, Wei He, Shuyue Wang, Donjeta Gjuka, Everett M Stone, Pooja Anil Shah, Jordi Rodon Ahnert, Taiping Chen, Xinli Liu, Mark T Bedford, Han Xu, Weiyi Peng
MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors. Journal for immunotherapy of cancer 12 (9) (2024)
Guanchao Ye, Guangyao Wu, Yu Qi, Kuo Li, Mingliang Wang, Chunyang Zhang, Feng Li, Leonard Wee, Andre Dekker, Chu Han, Zaiyi Liu, Yongde Liao, Zhen-Wei Shi
Non-invasive multimodal CT deep learning biomarker to predict pathological complete response of non-small cell lung cancer following neoadjuvant immunochemotherapy: a multicenter study. Journal for immunotherapy of cancer 12 (9) (2024)
Jason John Luke, Omid Hamid, Bernard A Fox, Paolo Antonio Ascierto, Iman Osman, James J Mule, Pedro J Romero, Michael T Lotze
Jeffrey S Weber, MD, PhD (1952-2024): in memoriam to discovery, friendship and family. Journal for immunotherapy of cancer 12 (9) (2024)
Jiawei Wang, Yuan Liang, Ao Xue, Jian Xiao, Xinyu Zhao, Shuqing Cao, Pengyu Li, Jiacheng Dong, Yuan Li, Zekuan Xu, Li Yang
Intratumoral CXCL13 + CD160 + CD8 + T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer. Journal for immunotherapy of cancer 12 (9) (2024)
Zelin Hou, Fengchun Lu, Jiajing Lin, Yuwei Wu, Linjin Chen, Haizong Fang, Linlin Chen, Shihan Zhang, Heguang Huang, Yu Pan
Loss of Annexin A1 in macrophages restrains efferocytosis and remodels immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway. Journal for immunotherapy of cancer 12 (9) (2024)
Qi Peng, Yuanyuan Xu, Xin-Sheng Yao
scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC. Journal for immunotherapy of cancer 12 (9) (2024)
Stefan Barisic, Elizabeth M Brahmbhatt, Elena Cherkasova, Timothy T Spear, Ujjawal Savani, Stephanie Pierre, Gina M Scurti, Long Chen, Muna Igboko, Rosa Nadal, Gang Zeng, Gordon Parry, David F Stroncek, Steven Highfill, Annika V Dalheim, Robert Reger, Michael I Nishimura, Richard W Childs
Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus. Journal for immunotherapy of cancer 12 (9) (2024)
Jie Mei, Jiahui Chu, Kai Yang, Zhiwen Luo, Jiayue Yang, Junying Xu, Qing Li, Yan Zhang, Qinglin Zhang, Mengyun Wan, Ningyi Xue, Junli Ding, Yichao Zhu, Yun Cai, Yongmei Yin
Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade. Journal for immunotherapy of cancer 12 (9) (2024)
Dan Mei, Ziyang Xue, Tianjing Zhang, Yining Yang, Lin Jin, Qianqian Yu, Jian Hong, Xianzheng Zhang, Jinru Ge, Li Xu, Han Wang, Ziwei Zhang, Yuchen Zhao, Yuanfang Zhai, Qianshan Tao, Zhi-Min Zhai, Qingsheng Li, Hongxia Li, Ling-Ling Zhang
Immune isolation-enabled nanoencapsulation of donor T cells: a promising strategy for mitigating GVHD and treating AML in preclinical models. Journal for immunotherapy of cancer 12 (9) (2024)
Tanya Ramadoss, Matthew Nichols, Christian Palacios, Zeynep Eroglu, Joseph Markowitz, Lilit Karapetyan, Ahmad A Tarhini, Evan J Wuthrick, Vernon K Sondak, Nikhil I Khushalani, Kenneth Y Tsai, Andrew S Brohl
Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma. Journal for immunotherapy of cancer 12 (9) (2024)
Yanyang Nan, Yu Bai, Xiaozhi Hu, Kaicheng Zhou, Tao Wu, An Zhu, Mengyang Li, Zihan Dou, Zhonglian Cao, Xumeng Zhang, Shuwen Xu, Yuanzhen Zhang, Jun Lin, Xian Zeng, Jiajun Fan, Xuyao Zhang, Xuebin Wang, Dianwen Ju
Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy. Journal for immunotherapy of cancer 12 (9) (2024)
Yanyang Nan, Yu Bai, Xiaozhi Hu, Kaicheng Zhou, Tao Wu, An Zhu, Mengyang Li, Zihan Dou, Zhonglian Cao, Xumeng Zhang, Shuwen Xu, Yuanzhen Zhang, Jun Lin, Xian Zeng, Jiajun Fan, Xuyao Zhang, Xuebin Wang, Dianwen Ju
Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy. Journal for immunotherapy of cancer 12 (9) (2024)